Extended Margin Compression Period
EBITDA margin recovery to 28-29% levels will not occur in FY24; management expects gradual improvement requiring FY25 to achieve historical margins. Q1 margin of 14.2% reflects severe operational deleverage.
LAURUSLABS / Q1-FY24 / risks
Keep the risk register visible.
Laurus Labs · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
high
ARV Pricing Headwinds Persist
While Q1 pricing erosion was minimal, prior year severe price cuts continue to impact revenues. Competition creating pricing headwinds in formulations despite stable volumes.
CDMO Revenue Opacity
Management declined to break down CDMO revenues by segment (human health vs. animal health vs. crop science) or provide revenue trajectory guidance for the next 2-3 years, making pipeline assessment difficult.
CapEx and Debt Trajectory Unclear
FY25 CapEx guidance deferred to September results; net debt expected to increase by INR 300-400 crore by March 2024 before declining in FY25. R3 equipment orders not yet placed (expected Q2), creating timeline uncertainty.